Pharmaceutical Product Development Inc. has struggled throughout 2009. The stock has not experienced the rebound seen in the broader market averages, and it remains down more than 30 percent year to date, trading last week around $20.
The company is a leading contract research organization, which provides outsourced clinical development services to companies trying to develop new drugs and medical devices. Pharmaceutical Product Development has relationships with most of the top-50 pharmaceutical and biotech firms.
No comments:
Post a Comment